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Introduction: Available data on the malignant solitary fibrous tumor 
of the pleura (mSFTP), a very rare neoplasm with unpredictable 
prognosis, are scarce. The aim of this study is to collectively analyze 
the aggregated data from the largest series in the English literature to 
date, a multicenter, 10-year study of 50-cases.
Methods: We retrospectively reviewed the clinical records of patients 
who underwent surgical resection for mSFTP in the period between 
January 2000 to July 2010. Long-term survival (LTS) and 5-year 
disease-free survival were analyzed in detail.
Results: There were 24 men and 26 women (median age, 66 years; age 
range, 44–83 years). Thirty-two patients (64%) were symptomatic. A 
malignant pleural effusion was diagnosed in 12 cases. Surgical resection 
included isolated mass excision in 13 patients and extended resection in 
35. In the remaining two cases only biopsies were undertaken. The resec-
tion was complete in 46 cases (92%). Adjuvant treatment was adminis-
tered to 15 patients. Median follow-up was 116 months (range, 18–311 
months). Overall LTS and disease-free survival were 81.1% and 72.1%, 
respectively. Fifteen patients (30%) experienced a relapse of the disease. 
Complete resection yielded much better LTS than partial resection 
(87.1% versus 0%; p < 0.001). At the Cox regression analysis, incomplete 
resection (hazards ratio [HR]: 39.02; 95% confidence interval [CI]:4.04–
380.36; p = 0.002) and malignant pleural effusion (HR: 3.44; 95%CI: 
0.98–12.05; p = 0.053) were demonstrated to be risk factors for ear-
lier death. At multivariate analysis, chest-wall invasion and malig-
nant pleural effusion increased the risk of recurrence (HR: 4.34; 
95%CI: 1.5%–12.6%; p = 0.007 and HR: 3.48; 95%CI: 1.1%–11.0%; 
p = 0.038, respectively).
Conclusions: Surgical resection remains the treatment of choice 
for mSFTP. Relapse is common (approximately 30%). Incomplete 
resection and malignant pleural effusion at diagnosis impact LTS 
negatively.
Key Words: Solitary fibrous tumor, CD34, Malignant solitary fibrous 
tumor, Localized fibrous tumor.
(J Thorac Oncol. 2012;7: 1698–1706)
The solitary fibrous tumor of the pleura (SFTP) is a rare neoplasm that accounts for less than 5% of all pleu-
ral tumors.1 Its incidence is approximately 2.8 cases out of 
100,000 registered hospitalized patients, and it usually occurs 
in all age groups with a peak incidence in the fourth and sixth 
decade of life.2,3 Since Klemperer and Rabin4 first described 
its pathologic characteristics in 1931, more than 900 cases of 
SFTP were reported in the literature up to 2005.5 According 
to several different authors, SFTPs have been characterized by 
dishomogenous taxonomies.6,7 The absence of a clear nomen-
clature has only added to the confusion about these tumors, 
where uncertainty exists with regard to their clinical behav-
ior; also, a sound classification with diagnostic and prognostic 
potential remains far from reach. The development of elec-
tron microscopy in the early 1980s and the introduction of 
immunohistochemistry techniques in the standard pathologic 
assessment of neoplasms have clarified that the tumor does 
not originate from the mesothelial layer but from the subme-
sothelial, noncommitted mesenchymal layer.8,9 Thus, the vari-
ous names used for this disease have slowly become unified, 
and the disease is now referred to as solitary (or localized) 
fibrous tumor of the pleura. Although the majority of these 
neoplasms have benign features (histological and clinical), 
approximately 10% to 20% of the cases reported in literature 
are malignant.10,11 Criteria for distinguishing pathologically 
benign forms from malignant ones have been established 
by England and colleagues,11,12 and these are now widely 
accepted. Easily controlled by surgical resection, benign forms 
have been reported to recur locally14 (this has been hypoth-
esized as related to a malignant transformation). Surgery, as 
well, remains the standard of treatment for malignant forms. 
The clinical decision-making process in malignant (m) SFT 
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(mSFT) management is supported, so far, by series of single-
case reports.1,12–15 To the best of our knowledge, in fact, the 
number of mSFTP reported cases is far too small for a sub-
stantial analysis of recurrence or survival rates: these, in fact, 
are inconsistently reported. The result is that no established 
treatment modality or follow-up plan has been yet agreed to. 
Also, the prognostic features of mSFTP do not seem to cor-
relate with its histological characteristics and this remains a 
point to be further clarified.11,16,17
We established a multicenter collaboration among 
high-volume thoracic surgery centers to collect a consistently 
homogeneous population (the largest so far in the English lit-
erature); we analyzed this population by reviewing its clini-
cal presentation, histopathologic characteristics, treatment 
modalities, and long-term survival (LTS) results. The outcome 
of this analysis is reported herein.
PATIENTS AND METHODS
In the period between January 2000 and July 2010, 50 
patients were surgically treated for malignant SFTP in the four 
centers involved in the present analysis (Catholic University of 
Rome [n = 9], Forlanini Hospital of Rome [n = 17], European 
Institute of Oncology of Milan [n = 8], and University of 
Turin n = 16]) and these formed the basis for this retrospective 
analysis. Before undertaking our data analysis, we obtained 
the approval of the Catholic University (Promoting Centre) 
Institutional Review Board for research use of retrospectively 
collected data (observational) stemming from standard clini-
cal practice. Data related to sex, age, tumor location, signs 
and symptoms, surgeons’ notes, pathological features, postop-
erative therapy, recurrence patterns, and long-term follow-up 
were systematically reviewed and recorded (see Table 1).
In all the patients, the preoperative evaluation included 
history, physical examination, routine blood tests, standard 
chest radiographs, and thoracic computed tomography (CT) 
scan. Fiberoptic bronchoscopy was performed in case of lesions 
located proximally to major airways. Electrocardiography, spi-
rometry, and arterial gas analysis were routinely performed and 
noted. Perfusion lung scan was performed only in selected cases 
as for echocardiography, which was carried out only if a history 
of cardiovascular disease was present or if a pneumonectomy was 
anticipated. 18-Fluorodeoxyglucose positron emission tomogra-
phy/CT was performed in two cases only. At pathological evalu-
ation, tumors were eventually reclassified as malignant when one 
or more of the criteria reported by England et al.9 were met: (1) 
mitotic count more than 4 mitoses/10 high-power fields; (2) pres-
ence of necrosis; (3) hypercellularity as judged by nuclear crowd-
ing and overlapping; and (4) presence of nuclear atypia.
Flow-cytometric analysis was performed on fresh mate-
rial. Immunostaining for a panel of cell markers including 
bcl-2 (apart from two cases), CD34 was routinely done in all 
four centers. Upon pathological re-review, immunohistochem-
istry was performed on formalin-fixed, paraffin-embedded tis-
sue, using the streptavidinbiotin immunoperoxidase method, 
in addition to standard hematoxylin and eosin staining (three 
sections for each case). In fact, the following antibodies were 
not routinely used: cytocheratin (AE1–AE3) and vimentin.
TABLE 1. Clinical and Pathological Results of the Population
Features Frequency
Sex
Female
Male
26 (52%)
24 (48%)
Age (mean ± SD) 65.9 ± 10.4
Follow-up (mean ± SD) 66.2 ± 52.9
Side 
Left
Right
Bilateral
Mediastinal
29 (58%)
18 (36%)
1 (2%)
2 (4%)
Pleural effusion 12 (24%)
Surgical procedures*
Isolated mass excision
Wedge Resection
Lobectomy
Pneumonectomy
Extended Resection
Chest wall
Diaphragm
Pericardial
Biopsy only
13 (26%)
23 (36%)
2 (4%)
4 (8%)
12 (24%)
10 (20%)
1 (2%)
1 (2%)
3 (6%)
Completeness 
Complete
Incomplete
46 (92%)
4 (8%)
Pathological chest-wall invasion (including pericardium  
and/or diaphragm)
12 (24%)
Pleural pattern
Parietal
Visceral
Intrapulmonary (inverted fibroma)
16 (32%)
30 (60%)
4 (8%)
Tumor size (mean ± SD) 12.8 ± 6.5
Peduncle 11 (22%)
ki-67% (mean ± SD) 14.8 ± 11.4
Mitosis (mean ± SD) 10.02 ± 8.7
Mitosis >4/10 HPF 31 (62%)
Necrosis or hemorrhagic areas 40/50 (84%)
High cellularity 42/43 (97.7%)
Cellular atypia 41/46 (89.1%)
England’s score
1 3 (5.9%)
2 1 (2.0%)
3 12 (23.5%)
4 24 (47.1%)
BCL2 46/48 (96%)
CD34 50/50 (100%)
Adjuvant 15 (30%)
Adjuvant radiotherapy 11 (22%)
Adjuvant chemotherapy 3 (6%)
Adjuvant radiochemotherapy 1 (2%)
Death 10 (20%)
Recurrence 15 (30%)
NED 32 (64%)
DOC 3 (6%)
DOD 8 (16%)
AWD 4 (8%)
*Combined procedures in seven cases.
NED, nonevidence of disease; DOC, dead for other causes; DOD, dead of disease; 
AWD, alive with disease. 
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A centralized pathological revision of the samples was 
performed by an expert—dedicated in lung pathology—
pathologist (PG) to avoid any variation in pathological diag-
nosis and to achieve a concordance on the histopathological 
characteristics of the samples reviewed.
Postoperative radiotherapy and/or chemotherapy were 
performed under the care of referring oncologists: although 
a certain degree of homogeneity was present within the four 
centers, this was lost when the centers are compared among 
themselves. After completion of the study (July 2010), infor-
mation about the health status of patients was obtained by the 
clinical records of outpatient clinics.
Statistical Analysis
The t test, the χ2 test and the Fisher’s exact test were used 
where appropriate. Actuarial patient survival and disease-free 
survival (DFS) were obtained by the Kaplan-Meier method. 
Comparisons between survival curves were done with the 
log-rank test. The Cox multiple regression analysis was 
subsequently applied and the risk factors for both the mortality 
and the relapse of the tumor were identified. Differences were 
considered significant at the level at which the p value was 
less than 0.05. All statistical analyses were conducted by using 
SPSS 13.0 for Windows (SPSS, Chicago, IL).
RESULTS
Clinical Presentation
Demographics and clinical and pathological features are 
summarized in Table 1. There were 26 women and 24 men with 
age ranging 44 to 87 years (mean ± SD: 66.0 ± 10.4 years). 
The tumor was right-sided in 29 patients (58%) and left-sided 
in 18 (36 %); in two cases the neoplasm was located in the 
mediastinum, and one patient presented with bilateral pleural 
lesions. At the time of diagnosis, 32 patients (64%) presented 
symptoms related to pleural fibroma, although no history of 
asbestos exposure was recorded; when symptoms were pres-
ent, the predominant ones were dyspnea, chest pain, and 
coughing. Eight patients (16%) had more than one symptom. 
Mild-to-severe hypoglycaemia (Doege-Potter’s syndrome) 
was observed in three cases (6%), and in one patient it was 
associated with weight loss, fatigue, and dysarthria. Eighteen 
patients (36%) were totally asymptomatic and pleural fibroma 
was incidentally found on a chest radiograph or more rarely on 
a CT scan performed for other reasons.
Preoperative Evaluation
Chest radiographs were obtained for the entire study 
group. In all patients but one, a preoperative CT scan was 
carried out. Usually, the density of the neoplasm was quite 
low (30–45 UH) and heterogenous to different extents in large 
tumors because of myxoid degeneration and localized hemor-
rhage or necrosis (Fig. 1A). Magnetic resonance imaging was 
obtained in four patients (8%) only.
A moderate-to-large malignant pleural effusion was 
observed in 12 patients (24%) (bloody fluid except in two 
cases). Material for cytological examination by transthoracic 
fine needle aspiration biopsy (FNAB) was obtained in 32 
cases (64%). The analysis showed the presence of malignant 
mesenchymal cells compatible with an mSFTP in 16 cases. 
This assessment provided a generic diagnosis of mesenchymal 
tumor with no other specifications in eight cases and failed to 
provide any result in the remaining eight.
Bronchoscopy was performed in 10 patients (20%). 
No abnormalities were found in seven cases; an extrinsic 
compression was present in three, and cytology on trans-
bronchial biopsy confirmed the diagnosis of mSFT in one 
of them. Overall, a certain diagnosis had been obtained in 
17 patients (34%).
Surgical Findings and Perioperative Outcome
All the patients were treated in one of the four institu-
tions as reported above. The operative approach and surgical 
procedures are summarized in Table 1. Tumors arising from 
the parietal pleura were more difficult to resect than those 
from the visceral pleura because they were large, affixed to 
the chest wall, and required extrapleural resection or extended 
resection.
When reviewing the surgical behavior in the four par-
ticipating centers it was clear that the extent of resection 
was decided on a case-by-case basis when the situation was 
appraised intraoperatively. In particular, an isolated mass exci-
sion was performed in 13 cases (26%) only whereas an en 
bloc resection of surrounding structures was carried out in all 
FIGURE 1.  Giant malignant solitary fibrous tumor of the pleura: Preoperative evaluation with (A) computed tomography scan; 
(B) surgical findings, and (C) pathological macroscopic features (dimension: 320 × 250 × 170 mm; weight: 2130 g).
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the remaining cases, as reported in Table 1. In six patients, 
a  formal lung resection (lobectomy [n =2] and pneumonec-
tomy [n = 4]) was necessary because of large tumors extend-
ing deeply in the lung parenchyma. A chest-wall resection 
was needed in 10 cases (20%) whereas in two cases the lung 
resection was extended to the diaphragm and/or the pericar-
dium. In the three cases in which the neoplasm was deemed 
unresectable or inoperable (extension to adjacent structures/
pleural malignant colonization—not previously detected at 
the preoperative workup) only a biopsy was performed.
Intraoperatively, a polypoid/pedunculated lesion 
(Fig. 1B) was observed in 11 cases (27%); 31 (73%) presented 
with sessile tumors. In eight cases the surgical report did not 
contain any indication about the gross morphology of the tumor 
and this could not be understood from the final pathology. 
The visceral pleura was considered the point of origin in 30 
patients (60%); and the parietal pleura in 16 (32%). In eight 
cases (16%) it was not possible to discriminate the exact 
point of origin of the disease because it extended largely into 
the pulmonary parenchyma and infiltrated the chest wall. 
Margins were intraoperatively confirmed free of tumor in all 
those cases (especially in the sessile morphology group) in 
which a doubt regarding the completeness of resection was 
present: a complete resection was achieved, as confirmed by 
final pathology, in all but four cases (92%) with three (6%) 
gross residual tumor (R2) situations (2 pleural carcinosis 
and 1 infiltration of the aortic arch) and one microscopic 
(R1), in a case where the neoplastic mass measured 25 cm 
circa in its maximum diameter and largely infiltrated the 
chest wall.
Postoperative Results and Adjuvant Therapy
The postoperative recovery was uneventful in 37 
patients (74%); complications occurred in 13 patients (26%) 
and these included: atrial fibrillation (n = 3), pneumonia 
(n = 3), bleeding (n = 3), which in one case required a rein-
tervention, pulmonary embolism (n = 2), persistent air leak 
(n = 1), and wound infection (n = 1). Two patients (4%) died in 
the perioperative period. One patient (a 78-year-old man) with 
no prior history of coronary artery disease died suddenly on 
postoperative day 3 because of a myocardial infarction after 
a left extended pneumonectomy with pericardial reconstruc-
tion for a very large tumor (24 cm of maximum diameter). The 
second patient (a 77-year-old woman) died on postoperative 
day 9 because of pneumonia complicated by massive pulmo-
nary embolism after a right upper lobectomy with combined 
chest-wall resection.
Fifteen patients (30%) underwent adjuvant treatment 
(radiotherapy in 11, chemotherapy in 3, and combined radio-
chemotherapy in 1 case). Clearly, the adjuvant treatment was 
substantially not homogeneously administrated in the cohort 
of patients analyzed in this report in which the clinical deci-
sion-making process was established by each single center.
Pathology
The tumors measured from 30 × 18 × 22 to 320 × 
250 × 170 mm (mean maximum axis =12.8 ± 6.5 cm; range, 
2–32 cm) and the largest one weighed 2130 g (Fig. 1C). 
Grossly, the majority of the tumors were well circumscribed, 
lobulated in appearance, and firm in consistency; the cut sur-
face was vaguely nodular storiform, occasionally microcystic 
and myxoid, and white-gray. On cut sections, tumors showed 
a whorled appearance, sometimes alternating with some 
myxoid areas.
Microscopically, the typical pathological findings of 
mSFTs were confirmed in all the specimens; in particular, a 
patternless pattern characterized by a proliferation of uniform 
elongated spindle cells with a various amount of connective 
tissue was detected in most of the cases. Sometimes, specifi-
cally fibrous or hypercellular patterns, along with mixed bun-
dles of tissue with marked amounts of blood vessels were seen 
in different sampled areas of the tumor (Fig. 2A). The diagno-
sis of malignancy was based on the four criteria by England 
et al., which we evaluated and eventually matched one by 
one, also arbitrarily extracting a risk-score (0–4) (Table 1) 
 thereafter to be correlated with prognosis.
The mitotic count was also evaluated in all patients 
and this ranged from 1 to 36 mitosis for 10 high-power fields 
(mean 10.02 ± 8.2). The proliferation index ki-67% was calcu-
lated in 38 of the 50 patients (mean ki-67% = 14.8% ± 11%, 
range, 1%–60%).
The immunohistochemical analysis showed in all tumors 
a positivity for vimentin and CD-34 (Fig. 2B and C), although 
no expression of low molecular weight cytokeratin and of des-
min was detected. A clear positivity for bcl-2 was found to be 
present in almost the entire cohort of patients (96%).
FIGURE 2.  Microscopical pathological findings (A) (hematoxylin and eosin × 100) of malignant solitary fibrous tumor; 
 immunohistochemical positivity staining for (B) CD34 and (C) bcl-2.
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Long-Term Survival
The follow-up was completed in 100% of the cases at 
the time of writing this report (median 52.5 months, range, 
1–194). Censoring found 40 patients alive and 10 dead. The 
overall LTS (Kaplan–Meier) was 81.1% (95% CI: ± 10.2%) at 
5 years and 66.9% (95% CI: ± 18.6%) at 10 years (Fig. 3A).
The most significant prognostic factor in our series 
proved to be the completeness of resection. In fact, patients 
with an R+ disease did not reach the 5-year survival, with a 
striking difference with R0 ones (overall: 87.1%, p < 0.001) 
(Fig. 4A). Interestingly, no differences in LTS was found when 
attempting a stratification of patients according to (1) the size 
of the tumor, (2) its pleural pattern (tumor arising from vis-
ceral versus parietal pleura), or (3) the pedunculated versus 
sessile morphology (Table 2). No evidence of different sur-
vival functions was found, similarly, stratifying for age and 
sex. Moreover, as stated above, we calculated a score (0–4) 
based on England’s criteria (Table 1); no significant differ-
ences were found when comparing the four classes with a 
trend for better survival in scores 1 and 2 (100% alive at 5 
years) if compared with scores 3 and 4 (90% and 79.6% alive 
at 5 years, respectively) (Table 2).
LTS was significantly worse for those patients with 
malignant pleural effusions if compared with those without 
(5-year LTS, 85.5% versus 69.4%; p = 0.04; (Fig. 4B). No 
further statistically significant difference was found, con-
sidering the other characteristics of the population, and this 
is very probably because of the relatively small number of 
observations.
As reported in Table 3, the Cox multiple regression 
analysis confirmed that the incomplete resection represents a 
risk factor for earlier death. In particular, it was estimated that 
patients with R+ resections had a risk of death 39.02 times 
higher than patients in whom an R0-resection was achieved 
(95% CI: 4.04–380.36; p = 0.002). The presence of malig-
nant pleural effusion had a heavily negative impact on survival 
with an estimated HR of 3.44 (95% CI: 0.98–12.05) and a 
p value almost statistically significant (p = 0.053). No other 
additional risk factors were evidenced.
Recurrence
During the follow-up period, 15 patients (30%) expe-
rienced a recurrence of the tumor (mean time to recurrence: 
34 months, range: 2–128). The recurrence pattern was local-
ized (intrathoracic) in six patients (40%) and diffuse (meta-
static) in nine (60%). Interestingly, in the entire population, no 
significant differences in the survival functions were observed 
between patients who experienced a recurrence versus those 
who did not (p = 0.371). In four patients with localized recur-
rences a re-resection was performed (in one case 3 further 
iterative resections were needed in a 4-year-long period). In 
all the other cases (2 with local relapse and 9 with metastases) 
chemotherapy was administered (in 2 combined with radiation 
therapy). The chemotherapeutic protocol was not uniform: 
most patients underwent single-agent treatment (doxorubin) 
or a combination of doxorubicin and ifosfamide; the clinical 
response was substantially unsatisfactory in almost all cases.
FIGURE 3.  Overall (A) LTS and (B) DFS in the entire cohort of patients. LTS, long-term survival; DFS, disease-free survival.
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For the entire population, the 5- and 10-year estimated 
DFS rates were 72.1% (CI 95%: ± 15.6%) and 60.5% (CI 
95%: ± 20.0), respectively. (Fig. 3B). The visual inspection 
of the disease-free curves suggested four factors potentially 
associated with the recurrence rate (Fig. 4C and D). In partic-
ular, the log-rank test confirmed that the patients who had an 
mSFTP involving the chest wall showed a lower rate of 5-year 
DFS (no chest-wall invasion 79.5% versus chest-wall invasion 
50%; p = 0.003); similarly, the analysis of survival demon-
strated a significantly worse DFS in patients with malignant 
pleural effusion (no pleural effusion 78.9% versus pleural 
effusion 55.6%; p = 0.023). Differently, no further pathologi-
cal or immunohistochemical features were associated with 
different DFS.
The Cox multivariable regression analysis confirmed 
that the presence of chest-wall invasion and the malig-
nant pleural effusion both increased the risk of recurrence 
(HR: 3.48, 95% CI: 1.1%–11.0%, p = 0.038; and HR: 4.34, 
95% CI: 1.5%–12.6%; p = 0.002, respectively) (Table 3).
DISCUSSION
SFTPs are uncommon neoplasms (with just over 900 
cases reported in the English literature in decades),5,6 but a 
pattern of augmented incidence could be detected in the recent 
years. Although the majority of these neoplasms are benign, 
approximately 10% to 20%10,11 show a more aggressive bio-
logical behavior, with pathological findings of invasiveness, 
appearance of distant metastases, and local relapse after 
resection. Sung et al.5 reported that the incidence of malignant 
SFTP varies from 7% to 60% in the English literature, a varia-
tion attributed to slight differences in the pathologic criteria 
differences used in each institution.
SFTs with malignant morphology and behavior are 
generally larger (mean tumor size of 12.8 cm in our series) if 
FIGURE 4.  Prognostic factors affecting (A and B) LTS and (C and D) DFS. LTS, long-term survival; DFS, disease-free survival.
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TABLE 2.  Overall Survival and Disease-Free Survival Results 
(Log-Rank Test)
Features
Log-Rank Test
Long-Term 
Survival p
Disease-Free 
Survival p
Sex
Male 77.7 0.67 81.8 0.19
Female 85.1 72.5
Age (yrs)
< 65 81.6 0.47 75.6 0.85
≥ 65 77.7 68.9
Side
Right 77.7 0.82 63.1 0.28
Left 83.3 92.3
Completeness
Complete 87.1 <0.0001 — —
Incomplete 25.0
Tumor size (cm)
< 12 83.6 0.81 74.0 0.48
≥ 12 78.0 69.3
Chest-wall invasion
No 85.6 0.22 79.5 0.003
Yes 68.2 50.0
Pleural effusion
No 85.5 0.04 78.9 0.023
Yes 69.4 55.6
Pleural pattern
Parietal 75.0 0.37 63.1 0.17
Visceral 82.1 74.4
Intrapulmonary  
(inverted fibroma)
100 100
Peduncle
No 80.0 0.11 80.5 0.88
Yes 100.0 59.3
Necrosis or hemorrhagic areas
No 78.8 0.26 83.3 0.95
Yes 81.7. 70.3
Mitosis
<4/10 HPF 79.2 0.36 76.2 0.77
≥ 4/10 HPF 82.1 69.9
Cellular atypia
No 100 0.24 100 0.13
Yes 77.3 65.9
High cellularity
No 100 0.52 100 0.53
Yes 84.7 74.0
England’s score
1 100.0 0.37 100.0 0.47
2 100.0 100.0
3 90.0 78.8
4 79.6 66.4
BCL2
Yes 79.6 — 69.8 —
CD34
Yes 79.1 — 72.1 —
ki-67%
<15% 69.7 0.12 87.7
≥ 15% 83.3 77.5 0.6
Recurrence
No 87.8 0.37 — —
Yes 70.0
HPF, high-power field; ki-67%, proliferation index.
(Continued)
compared with benign ones,18,19 significantly so in some stud-
ies,20,21 though very large tumors can be also benign. Some 
authors suggest that larger tumors are more likely to be malig-
nant because they have had time to undergo genetic changes.22
Furthermore, the symptoms, if any, are more frequently 
associated with malignancy.5 Intrathoracic symptoms are 
usually nonspecific and include cough, chest pain, and dyspnea. 
Possible causes may be: (1) the irritation of adjacent structures 
by invasion or peritumoral adhesion, (2) the paracrine action 
of unknown factors secreted by the mSFTP, or (3) the presence 
of pleural effusion (which is generally more frequent in 
those malignant tumors). Indeed, according to England and 
colleagues,11 pleural effusion affects 16% of the patients, with 
a higher prevalence (32%) among those with mSFTP (8% 
in those with benign tumors). In the present series, we could 
detect a malignant pleural effusion in 12 patients (24%) and, 
very interestingly, these patients had a significantly worse 
prognosis in terms of LTS (69.4% versus 85.5%, p = 0.04) and 
DFS (55.6% versus 78.9%, p = 0.023) if compared with those 
without any sign of pleural effusion. This finding probably 
reflects a more advanced stage of the disease in which the 
presence of pleural fluid can be considered the expression of a 
pleural direct invasion or dissemination (M+ disease).
There is also evidence that the hypoglycemia has a para-
neoplastic syndromic appearance and is related to the produc-
tion of insulin-like growth factor II by the tumor cells; in fact, 
it normally resolves after the removal of the tumor itself.5,23 
The incidence of hypoglycemia varies from 2% to 4%3,8,14 and 
topped at 6% in our series (possibly because of the greater 
representation of malignant forms).
TABLE 3.  Cox Proportional Hazards Model of Factors 
Affecting LTS and DFS
Features
Cox Hazards Model of 
Factors Affecting Long-
Term Survival
Cox Hazards Model 
of Factors Affecting 
Disease-Free Survival
Hazard Ratio
(95% CI) p
Hazard Ratio
(95% CI) p
Pleural effusion 3.44
(0.98–12.05)
0.053 3.48
(1.1–11.00)
0.033
Incomplete 
resection
39.02
(4.04–380.36)
0.002 N/A N/A
Chest-wall 
invasion
— Ns 4.34
(1.49–12.53)
0.007
CI, confidence interval; N/A, not available; Ns, not significant.
Bold indicates P values less than 0.05.
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Although the chest CT scanning remains the test of 
choice, the radiological differentiation between the benign or 
malignant nature of the neoplasm remains difficult. However, 
the following findings could suggest malignancy: a diameter 
exceeding 10 cm, central necrosis, and ipsilateral pleural effu-
sion, according to criteria described in the work by Ferretti 
et al.24 Nuclear magnetic resonance may provide some help, 
showing the fibrous character of the lesion25 and by providing 
a topographic and differential diagnosis and differentiating the 
tumor from surrounding structures. Although FDG/positron 
emission tomography-CT has been demonstrated to be useful 
in selected mSFTP cohorts because it provided some differen-
tial diagnostic elements to distinguish benign and malignant 
variants of the tumor,18,26 further evidence is needed for this 
methodology to be routinely inserted in the mSFTP clinical 
workup guidelines. Even the cytological assessment of these 
neoplasms in the preoperative setting is invariably unsatisfac-
tory because the accuracy of the CT-guided FNAB procedure 
ranges in levels below 50%.18,20,26,27 We share the opinion that 
FNAB should be reserved for those cases in which the clinical 
condition contraindicates surgery (for functional and/or onco-
logical reasons).
Surgery is the first step treatment of choice for mSFTPs 
and the completeness of the resection represents its primary 
objective.11,12 An extended resection through standard tho-
racotomy should be performed to warrant completeness of 
the resection. Video-assisted thoracic surgery procedures 
have been sometimes used (in 10% only of our population) 
because these approaches cannot guarantee the completeness 
of the resection, especially in large and invasive/malignant 
tumors. However, in those cases in which the pedunculated 
morphology is accompanied by the absence of pleural dis-
semination and/or chest-wall clear infiltration, we believe 
that video-assisted thoracic surgery can be reasonably used. 
We suggest intraoperative checking of the surgical margins to 
confirm the radicality of the excision when this approach is 
used. In the present series, pulmonary wedge excision was the 
most common surgical procedure, whereas formal anatomic 
lung parenchymal resections alone were performed in only 
six patients (12%). Chest-wall resection alone was required 
in three patients (6%) whereas in seven patients (14%) it was 
combined with additional lung parenchymal resection. The 
operative approach and extent of surgical excision is clearly 
dictated by the mSFTP’s size, location, and attitude toward 
surrounding structures.
The final diagnosis of malignancy in the cases reported 
in this review was established on the basis of histological cri-
teria suggested by England et al.11 These criteria are currently 
widely accepted and have been employed in the most recent 
surgical series,12–15,27 and their usefulness is also suggested by 
the American Registry of Pathology.28 In our series we did not 
observe the pleomorphic variant as described by Perrot et al.,6 
in which isolated pleomorphism can be detected without any 
other sign of malignancy (England score 1) and that is gener-
ally considered as an intermediate form, borderline with frank 
malignancy.
Regarding the long-term outcome after surgical resec-
tion, we may assume that LTS after resection of mSFTPs is 
possible because it ranges from 46% to 100% in the main 
surgical series reported until now (77.6% in the present 
series; Table 4).
In agreement with other authors,5,11,15,18,20,27 our data 
demonstrated an LTS is dramatically better (84.9% ver-
sus 0%) when a complete resection is achieved (Fig. 3A). 
Univariate analysis shows that patients with invasion of neigh-
boring structures and with malignant pleural effusion have a 
worse DFS; furthermore, the multivariate analysis confirmed 
the invasion of neighboring structures as the only independent 
factor impacting significantly on the recurrence rate of the 
disease (Table 3). Regarding the tumor size, differently from 
some studies,11,17,21 we could not confirm the tumor size as 
a factor significantly impacting survival, in agreement with 
other authors.18,29 Similarly, we found that prognosis was not 
affected by the site (visceral or parietal pleura) of origin or by 
the gross morphologic features of the tumor (sessile versus 
peduncolated) (Table 2). In this setting, Perrot and colleagues6 
classified SFTP on the basis of a combination of gross mor-
phologic features and pathologic subtype (benign peduncu-
lated, benign sessile, malignant pedunculated, and malignant 
sessile). The authors reported significant differences in the 
recurrences and survivals of these subgroups and in particu-
lar, the recurrences were reported to occur in 63% of those 
patients with sessile mSFTPs and in 14% of patients with 
peduncolated mSFTPs. Of all the patients enrolled in the pres-
ent study, morphopathologic information could be obtained 
in 42 cases: 31 were sessile mSFTPs and 11 pedunculated. 
Local recurrence occurred in seven patients (21.6%) and four 
patients (36.4%). Although our data are not completely in line 
with those from Perrot et al.,6 we should also consider that: 
(1) our sample is composed basically by a surgical series, (2) 
all patients were surgically treated in high-quality and high-
volume surgical centers with a very high resection complete-
ness rate (≤ 92%). The significant differences of the analyzed 
series could justify this observation. We are of the opinion that 
the Perrot morphopathological classification, although useful, 
should be further validated regarding its prognostic potential 
in large prospective series. On a different note, when data 
from our cases are matched with England’s criteria, we could 
detect a linear correlation with DFS shortening according to 
the increase of the score; in fact mSFTPs with scores 3 to 4 
were associated with a DFS rate of 78.8% and 66.4% whereas 
all cases of mSFTPs with scores 0 to 1 were 100% free from 
recurrence at the moment of the follow-up.
TABLE 4.  Early and Long-Term Results after Surgical 
Treatment of mSFTP
Series # Radicality (%)
Long-Term 
Survival (%)
Recurrence 
Rate (%)
Rena15 8 100 100 13
Magdeleinait27 22 95 89 14
Sung5 19 89 58 42
Harrison20 11 100 46 4
Cardillo18 15 100 87 27
Present series 50 92 77.6 30
Review of data extrapolated from other series.
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Therefore, our results, although based on a rela-
tively small cohort of observations, allow us to confirm that 
England’s criteria may have a prognostic value. Adjuvant 
treatment did not induce, in our series and in agreement with 
others,12 any significant benefit to the overall survival of oper-
ated patients. On the contrary, we could detect a trend showing 
a negative impact. Nevertheless, we believe that this observa-
tion is clinically irrelevant because of the great heterogeneity 
of criteria that led, in each center, to the indication of adjuvant 
treatment. Finally, we could confirm the fact that SFTP, despite 
their tendency to grow locally, have a malignant behavior that 
justifies a full long-term follow-up. In the surgical R0 popula-
tion, the recurrence rate (local plus distant) ranges from 14% 
to 86%5,12,27,30 (30% in our series, 15 cases of which 9 with 
evidence of distant metastasis). This behavior also justifies an 
aggressive surgical strategy where redo resection should be 
performed in all cases in which it is reasonably possible. Our 
long-term results on the four redo surgery cases, in line with 
others,15,31 support this attitude.
Limitations and Strengths
This is a retrospective analysis and, as such, has sig-
nificant limitations in solving the uncertainties regarding the 
SFTPs. However, the relatively large number of observed 
cases, the homogeneity of the cohort, the long-term follow-up 
information (10 years), and the comprehensive analysis of the 
prognostic factors we have performed support the conclusion 
that radical surgery and redo surgery, if performed in selected 
high-volume centers, are able to achieve a more-than-satis-
factory disease control in a biological setting, in which so far, 
alternative treatments (radio and chemotherapy) have failed to 
provide significant benefits.
CONCLUSIONS
Surgical resection, when technically and medically fea-
sible, is recommended for the treatment of localized mSFTP, 
and long-term survivals could be expected. Additional prog-
nosis stratifiers must be further investigated and validated.
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